

2020 Conference Announcement Pharmaceutical Bioprocessing

Venue and Subject-Euro Pharma 2020

Frankfurt, Germany is the largest city of German federal state of Hesse and fifth largest city of Germany. Located in southwestern Germany and in the neighbouring cities of Wiesbaden and Mainz, the city is a global destination for commerce, culture, education, tourism and transportation. It occupies both sides of the Main River and is year-around destination known for its trade fairs. Being the second largest metropolitan region of Germany, Frankfurt is the site of many global and European corporate headquarters including that of the European central bank, Frankfurt Stock Exchange, Deutsche Bundesbank, DZ Bank and other institutes. Technology and research, services, consulting, automotive and other industries complement the economic stability of the city.

The city is a pinpoint of several educational institutions, including the UAS, and FUMPA. The city is also characterized by the eminent football clubs, museums, botanical gardens, renowned DJs and theatres.

Considered a global city - it frequently ranks in the top ten best cities to live and do business - Frankfurt has also long been an important centre for cultural and tourism activities. Its huge trade fair complex, Messe Frankfurt, hosts important events such as the Frankfurt Book Fair (the world's most important publishing event). The city is known for its exceptional number of fine museums covering art, science, and history.

The fast-growing division of the pharmaceutical market includes generics and biologics. Biologics now account for over a third of all new drugs in clinical trials or awaiting FDA approval. 15 U.S generic drug sales reached an estimated \$70 billion, representing a quarter of the global market, due to a large number of drugs going off-patent and healthcare reforms favouring generics. Although generics make up only 22 percent of total prescription sales, its share of filled prescriptions has risen from 19 percent in 1984 to 88 percent in 2015. The research-based pharmaceutical industry is estimated to have spent nearly USD 149.8 billion globally on pharmaceutical R&D in 2015-16. Among all the industrial sectors, the research-based pharmaceutical industry has consistently invested the most in research and development, even in times of economic turmoil and monetary crisis.

The global market for drug discovery technologies and products was worth \$38.4 billion in 2011. This figure is projected to reach \$41.4 billion in 2012 and \$79 billion in 2017, a five-year compound annual growth rate (CAGR) of 13.8%. There is a need to impede serious adverse effects caused by the drugs by enhancing drug targeting through research in pharmacology.